# Formal Verification of Blood Transfusion Compatibility Rules

*"First, do no harm." — Hippocrates*

**Charles C Norton**

4 December 2025

---

## Abstract

This document describes a machine-verified specification of ABO/Rh blood group compatibility for transfusion medicine, implemented in the Coq proof assistant. The formalization encodes compatibility rules for packed red blood cells, fresh frozen plasma, platelets, cryoprecipitate, whole blood, and granulocyte concentrates. Extended antigen systems (Kell, Duffy, Kidd, MNS, Lutheran, Diego) and HLA/HPA/HNA polymorphisms are modeled. Population allele frequencies for 105 countries are included with Hardy-Weinberg equilibrium calculations.

## Methods

Compatibility predicates are defined as computable boolean functions over the product type `(ABO × Rh)`. Safety properties are expressed as propositions and proven by case analysis, decidability arguments, and computational reflection. The specification distinguishes ABO compatibility (determined by naturally occurring isoagglutinins) from Rh compatibility (determined by acquired alloimmunization status and clinical context including female patients of childbearing potential).

Recipient modeling incorporates ABO subtypes (A₁, A₂, A₃, Aₓ, Aₑₗ, acquired B, cis-AB, Bombay, para-Bombay), Rh variants (weak D types 1–5, partial D categories DII–DVII, DEL), and sensitization history. Antibody evanescence is modeled for Kidd system antibodies with titer-dependent half-life decay.

## Principal Results

The following properties are proven:

1. Type O Rh-negative erythrocytes are compatible with all recipient phenotypes.
2. Type O Rh-negative is the unique blood type satisfying universal compatibility.
3. Type AB Rh-positive recipients may receive erythrocytes from any ABO/Rh phenotype.
4. Rh-negative recipients cannot safely receive Rh-positive erythrocytes (absent clinical override).
5. Plasma compatibility follows the inverse of erythrocyte compatibility with respect to ABO.
6. Bombay phenotype recipients require Bombay phenotype donors exclusively.

## Compilation

```
coqc transfusion_safety.v
```

Requires Coq 8.16 or later. Compilation produces `transfusion_v2.ml` via extraction.

## Limitations

MFI threshold values for HLA antibody detection are instrument-specific and require laboratory validation prior to clinical implementation. Population frequency data are derived from published sources and may not reflect local patient demographics. This specification has not been validated for clinical decision support. Verification against institutional protocols is required before deployment.

## References

AABB Technical Manual, 20th Edition. Fung MK, Eder AF, Spitalnik SL, Westhoff CM, eds. AABB Press; 2017.

Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology. 2009;25(2):48-59.

Westhoff CM. The structure and function of the Rh antigen complex. Semin Hematol. 2007;44(1):42-50.

Denomme GA. Kell and Kx blood group systems. Immunohematology. 2015;31(1):14-19.

---

MIT License
